GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genedrive PLC (LSE:GDR) » Definitions » ROCE %

Genedrive (LSE:GDR) ROCE % : -267.08% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Genedrive ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genedrive's annualized ROCE % for the quarter that ended in Dec. 2023 was -267.08%.


Genedrive ROCE % Historical Data

The historical data trend for Genedrive's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genedrive ROCE % Chart

Genedrive Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -78.65 -273.85 -27.29 -122.03 -155.13

Genedrive Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -97.16 -83.50 -116.85 -233.68 -267.08

Genedrive ROCE % Calculation

Genedrive's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=-5.95/( ( (6.621 - 1.01) + (4.507 - 2.447) )/ 2 )
=-5.95/( (5.611+2.06)/ 2 )
=-5.95/3.8355
=-155.13 %

Genedrive's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=-4.762/( ( (4.507 - 2.447) + (3.439 - 1.933) )/ 2 )
=-4.762/( ( 2.06 + 1.506 )/ 2 )
=-4.762/1.783
=-267.08 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genedrive  (LSE:GDR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Genedrive ROCE % Related Terms

Thank you for viewing the detailed overview of Genedrive's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genedrive Business Description

Traded in Other Exchanges
Address
48 Grafton Street, The Incubator Building, Manchester, GBR, M13 9XX
Genedrive PLC is a holding company engaged in the molecular diagnostics business. It operates in one operating segment named Diagnostics which is engaged in the Genedrive Point of need molecular diagnostics platform for the diagnosis of infectious diseases and use in patient stratification (genotyping), pathogen detection, and other indications. Geographically the majority of the revenue is derived from the United Kingdom.

Genedrive Headlines

No Headlines